Micro-costing Diagnostics in Oncology: From Single-Gene Testing to Whole Genome Sequencing

Clémence TB Pasmans¹, Bastiaan BJ Tops², Elisabeth MP Steeghs³, Veerle MH Coupé⁴, Katrien Grünberg³, Eiko K de Jong³, Ed MD Schuuring⁵, Stefan M Willems⁶, Marjolijn JL Ligtenberg³, Valesca P. Retèl⁹, Hans van Snellenberg¹¹, Ewart de Bruijn¹¹, Edwin Cuppen¹¹, Geert WJ Frederix¹

Affiliations

- ¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
- ² Princess Máxima Center for Pediatric Oncology, PO Box 113, 3720 AC Bilthoven, The Netherlands
- ³ Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
- ⁴ Department of Epidemiology and Biostatistics, Amsterdam University Medical Center, VU Amsterdam, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
- ⁵ Department of Pathology, University of Groningen, University Medical Center Groningen, PO Box 30001, 2300 RB Groningen, The Netherlands
- ⁶ Department of Pathology, University Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The Netherlands
- ⁷ PALGA Foundation, 3991 SZ Houten, The Netherlands
- ⁸ Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands

⁹ Department of Psychosocial Research and Epidemiology, Netherlands Cancer

Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands

¹⁰ Department of Health Technology and Services Research, University of Twente,

PO Box 217, 7500 AE Enschede, The Netherlands

¹¹ Hartwig Medical Foundation, Science Park 408, 1098 XH Amsterdam, The

Netherlands

¹² Center for Molecular Medicine and Cancer Genomics Netherlands, University

Medical Center Utrecht, Utrecht University, PO Box 85500, 3508 GA Utrecht, The

2

Netherlands

Corresponding author:

Geert W.J. Frederix

Julius Center for Health Sciences and Primary Care

University Medical Center Utrecht

Office number Stratenum 6.131

PO Box 85500

3508 GA Utrecht

Tel: +31 88 75 681 88

Email: G.W.J.Frederix@umcutrecht.nl


Abstract

Purpose: Predictive diagnostics play an increasingly important role in personalized medicine for cancer treatment. Whole genome sequencing (WGS) based treatment selection is expected to rapidly increase worldwide. Detailed and comparative cost analyses of diagnostic techniques are an essential element in decision-making. This study aimed to calculate and compare the total cost of currently used diagnostic techniques and of WGS in treatment of non-small cell lung carcinoma (NSCLC), melanoma, colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST) in the Netherlands.

Methods: The activity-based costing (ABC) method was conducted to calculate the total cost of included diagnostic techniques based on data provided by Dutch pathology laboratories and the Dutch centralized cancer WGS facility. Costs were allocated to four categories: capital costs, maintenance costs, software costs and operational costs. Outcome measures were total cost per cancer patient per included technique, and the total cost per cancer patient per most commonly applied technique (combination) for each cancer type.

Results: The total cost per cancer patient per technique varied from € 58 (Sanger sequencing, 3 amplicons) to € 4738 (paired tumor-normal WGS). The operational costs accounted for the vast majority over 90 % of the total per cancer patient technique costs. The most important operational cost drivers were consumables followed by personnel (for sample preparation and primary data analysis).

Conclusion: This study outlined in detail all costing aspects and cost prices of current and new diagnostic modalities used in treatment of NSCLC, melanoma, CRC and GIST in the Netherlands. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support



Words: X

Keywords

Micro-costing, whole genome sequencing, standard diagnostic techniques, oncology, personalized medicine

Introduction

Newly developed medicines (targeted therapies and immunotherapies) play an increasingly important role in treatment of cancer (1–2). However, only subgroups of patients respond to these (mostly expensive) treatments (3–6). Patients who do not respond can experience serious side effects. Matching each patient to the appropriate therapy is complex and as a consequence, not all patients receive the treatment they could have benefitted from (3–5). This calls for a better patient selection, improvement of personalized treatment and thereby expectantly improving the patients' life expectancy, experienced quality of life and reducing health care costs. Optimal predictive diagnostics in molecular pathology are necessary to determine which therapy is most appropriate for a patient (7–10).

In predictive diagnostics of somatic molecular analyses in pathology, various techniques can be used to depict genetic characteristics of a tumor. Single-gene analysis or sequencing of targeted gene panels (TGP) using next generation sequencing (NGS) techniques, or a combination of the two, are routine practice in the diagnostics trajectory for different cancer types (11). In current clinical practice, there is large variation in both the frequency and type of technique used for the selection of cancer treatment (12). In comparison, the advanced diagnostic technique of whole genome sequencing (WGS) is currently only applied in research context in oncology.

The main advantage of WGS, in contrast to TGP, is that it is able to detect all types of DNA alterations (i.e. mutations, copy number alterations, structural variants, tumor mutational burden and DNA repair status) of the tumor (13–14). It increases the chance of optimal treatment selection, and determines eligibility of patients for clinical

trials as many study inclusion markers are not included in standard diagnostic gene panels. From a technical point of view, WGS could therefore replace a multitude of currently used diagnostic techniques, but it comes at a higher cost. Recent costing studies have indicated that costs range from \in 265 to \in 309 for single-gene techniques (12), from \in 376 to \in 968 for small TGPs (5–50 gene panels (15–16), \sim 50 gene panels (12)), and from \in 333 to \in 1948 for larger TGPs (> 50 gene panels (15), 90 gene panels (17)) in 2014–2015. The cost of WGS per cancer patient (paired tumor-normal) was estimated at \in 6676 (17) and at \in 5645 (18) in 2015–2016, at \$ 4484 (about \in 3870) in 2017 (19), and at \in 6841 (about \in 7501) in 2019 (20) (\in 1669, \in 1411, \$ 1121, \in 3420 per genome equivalent, respectively).

These studies performed micro-costing analyses. Some studies specifically made use of the activity-based costing (ABC) method, a process-based cost allocation technique (21). Nevertheless, results are difficult to compare, as included cost components differed among all studies as well as the interpretation of process steps, and, as such, the incorporated related costs. Cost drivers are anticipated to be platform utilization (12, 18) and consumables (14, 15–18).

The implementation and use of WGS is expected to rapidly increase worldwide in the coming years (13–14). A variety of reasons underlie this prospect. Namely, the increasing availability of targeted drugs (1–2), and the increased registration of pancancer drugs (22), leading to an increase in needed tests and accumulation of sequential tests. Therefore, it is essential to determine both costs and effects of WGS-based treatment selection versus current practice in an economic evaluation. Such evaluations encompass complete overviews of all costs and effects involved in

a specific disease area, from diagnostics to treatment and hospitalization. Detailed

and comparative cost estimations of diagnostic techniques are required. These are

important in assessing the added value (in monetary terms) of new diagnostic

modalities, and in providing insight when to replace standard diagnostic techniques

with these new modalities.

To the best of our knowledge, no previous research investigated the costs of

currently used diagnostic techniques and WGS in the context of predictive testing in

cancer treatment selection using a consistent and uniform costing method.

Therefore, we performed a micro-costing study using similar process-based cost

calculations of the different diagnostic techniques application across Dutch pathology

laboratories (hereinafter referred to as labs) and WGS used in a central lab. We

aimed to calculate and compare the total cost of currently used diagnostic techniques

and of WGS in treatment of NSCLC, melanoma, colorectal cancer (CRC) and

gastrointestinal stromal tumor (GIST) in the Netherlands.

Methods

Data availability

The data used for the study were obtained from 24 Dutch labs and the cancer WGS

facility of Hartwig Medical Foundation (HMF) in the year 2018. The predictive

diagnostic techniques included from the participating labs were techniques that are

currently used for treatment selection of advanced NSCLC, melanoma, CRC or

GIST. This led to the inclusion of following techniques: immunohistochemistry (IHC),

Fluorescence In Situ Hybridization (FISH), pyrosequencing (Pyro seq), High

Resolution Melting (HRM), Sanger sequencing (Sanger), NGS gene panels, Cobas

and Biocartis. In this study, the costs of certain techniques were subdivided regarding

their target genes (Sanger and Biocartis), cancer hotspot panels (NGS) or protein

expression (IHC).

Included techniques were selected based on an inventory at participating labs. These

labs received a questionnaire to obtain information about most frequently used

techniques in treatment of the different cancer types. In addition, the frequency of

technique usage was extracted from the nationwide network and registry of histo-and

cytopathology in the Netherlands (PALGA) (23), which contains the digital pathology

reports of all 46 Dutch pathology laboratories since 1971. The inventory was

performed between 01-10-2017 and 30-09-2018 and was substantiated with

feedback moments to the labs in order to ensure additional validity. Data on

technique frequency usage are available in Supplementary Table 1.

Information about WGS was obtained from the HMF facility, a centralized

independent organization focused on clinical-grade WGS of cancer patients. WGS-

based analyses were performed as part of clinical trial studies involving treatment of

all types of cancer patients, so regardless of cancer type.

Micro-costing design

The cost calculations for the different diagnostic techniques used in the Netherlands

were performed using the ABC method (21). For this purpose, a measurement plan

8

was created including the essential cost components.

The most frequently used techniques in treatment of NSCLC, melanoma, CRC and GIST were defined by the participating 24 Dutch labs. Per technique, three labs, if possible, using the specific technique were consulted to determine the costs by filling out the measurement plan. In an organized meeting, consensus was reached between the labs concerning these measurement plans. Consensus was not based on averaging of cost prices of different labs, but rather based on an 'average' lab with realistic samples numbers, accepted protocols and equipment. The measurement plans were sent back and forth several times for feedback after this meeting. Additionally, supplier standard list prices were requested and received for consumables, and for acquisition and maintenance of the platforms. Together, this led to a cost overview with final cost prices related to the test, data analysis and reporting process per technique, per cancer type.

With regard to WGS, a measurement plan was completed by the HMF facility, which corresponded to the one filled out by the labs. The test, data analysis and reporting process was expressed in a final cost price. The final cost price estimation was based on utilization in a decentralized setting, or an average Dutch lab practice, and standard list prices of the supplier for acquisition and maintenance of the platforms and for consumables.

In sum, a so called standard case perspective was maintained in calculating the base case cost prices for all techniques for the purpose of realistic cost comparison. This means that an average lab practice was assumed, and suppliers' standard list prices were used, concerning all techniques. The assumptions underlying the cost

calculations are shown in Table 1, which are all based on the standard case perspective.

Allocation of costs

Costs directly related to the test, data analysis and reporting process were taken into account. Costs that are associated with obtaining the material (blood and tumor biopsy withdrawal), DNA extraction in both tumor and blood, and overhead costs were excluded. Included costs were allocated to four categories: capital costs, maintenance costs, software costs and operational costs.

Capital costs were fixed costs of the platforms. The life cycle, interest rate and annuity factor of the various platforms were used in calculating the annual capital costs per cancer patient. Maintenance costs were annual returning fixed costs for platform maintenance. No maintenance costs were taken into account for the first year as the platforms have a warranty for the first year. The annual maintenance costs were estimated per cancer patient for the other years. Software costs involved either software acquisition (license) costs or costs incurred for daily supervision and maintenance of the pipeline, and were calculated per cancer patient. Operational costs consisted of costs incurred for the process of analysis, such as consumables, personnel for sample preparation, primary data analysis, interpretation and report, and data processing and storage. These operational costs were also estimated per cancer patient. Finally, total cost per cancer patient was calculated by summing up all the calculated total costs per cost category.

Analyses

Base case analysis

The base case analysis was performed from the earlier defined standard case

perspective based on the assumptions described in Table 1. The primary outcome

measure of interest was the total cost per cancer patient per included technique.

The second outcome measure included the total cost per cancer patient per most

frequently applied technique (combination). Only those techniques used for targeted

therapy stratification based on genomic aberrations were considered (so excluding

IHC testing (programmed death ligand 1 (PD-L1) protein expression as is included in

Table 1 and 2). The total cost per technique was calculated for each cancer type

separately with a maximum of three different technique combinations ordered by

technique frequency usage. WGS was included as a sole potential future practice for

all cancer types for which combinations with other techniques were redundant.

For standard techniques to be included, the following condition had to be met: the

technique should be performed in ≥ 2 labs (inventory labs) and included ≥ 5 % of the

analyses in total for the respective cancer types (PALGA data; Supplementary Table

1). This led to the inclusion of NGS gene panels, Sanger, HRM, IHC and FISH.

These techniques covered at least 80 % of the performed analyses per cancer type

(Supplementary Table 1). In addition, WGS was included based on application at the

11

HMF facility only.

Sensitivity analysis

In order to obtain a representation of the variation in technique usage and associated

process costs, across all 24 labs, the distribution of costs were mapped around the

average. Moreover, as the HMF facility is currently one of few WGS testing suppliers

in the Netherlands, their actual practice was taken into account as a sensitivity

analysis. Finally, two anticipated cost drivers were selected for this sensitivity

analysis: utilization of the platforms and the cost of consumables, based on previous

research (12, 14, 15–18). The extent of variation of these parameters were based on

lab- and HMF-specific practices in the year 2018.

For the sensitivity analyses, only techniques included in the base case analysis

concerning the second outcome measure were taken into account. A margin of + 15

% and - 15 % around the calculated average platform utilization for the standard

techniques applied by different included labs was deemed to be a realistic variation.

Therefore, utilization of the platforms varied from 17 to 47 % for NGS gene panels

(average 32 %), 39 to 69 % for Sanger (average 54 %), 13 to 43 % for HRM

(average 28 %), 15 to 45 % for IHC (average 30 %) and 9 to 39 % for FISH (average

24 %). For WGS, the average platform utilization was varied to the actual practice

use by + 30 %: from 60 % to 90 %. The cost of consumables was reduced in the

sensitivity analysis by 30 % for all the techniques, which was based on the

reasonable expectation of discounts from the suppliers.

Results

The assumptions underlying the cost calculations for the application of the included

diagnostic techniques are depicted in Table 1. The Table shows all values of the

various factors based on the standard case perspective as outlined for both standard diagnostics and WGS below.

Standard diagnostics

For each of the included standard diagnostic techniques one tumor sample is needed, corresponding to the test of one cancer patient. The number of samples that can be analyzed per run and the sequencing depth were based on the concerning supplier specifications. Furthermore, suppliers' standard list prices were used as cost of acquisition and maintenance of the platforms, and as cost of consumables. Utilization of the sequencing platform, personnel time needed for sample preparation, primary data analysis, data interpretation and report, are all based on the standard practice of an average lab using the technique. Gross hourly salaries of the laboratory technician, bioinformatics technician, clinical molecular biologist, and pathologist were based on Dutch hospital collective employment agreement 2018 costs.

WGS

The calculations for WGS are based on the sequencing platform NovaSeq 6000 from Illumina, which is used in the HMF facility. Furthermore, a liquid handler is included for sample preparation. Per cancer patient two samples are needed for the sequence analysis: one tumor and one reference (blood) sample, which allows the necessary tumor to normal comparison. The sequencing unit for WGS is a sequencing depth of 30x coverage. In applying WGS, two sample preparations and four sequencing units are needed. The four sequencing units include three times 30x coverage of the tumor (to compensate for tumor purity heterogeneity) and one time 30x coverage of the

reference sample. Acquisition and maintenance costs of the platforms are based on

utilization of the technique in an average Dutch lab practice. The costs of

consumables are based on Illumina's standard list prices, not taking into account

discounts. In line with the standard case perspective, the number of samples per run

and runs per year are 24 and 208, respectively, with a 60 % utilization of the

sequencing platform. Furthermore, personnel time needed for sample preparation,

primary data analysis, data interpretation and report, are all based on standard

practice of an average lab. Data processing and data storage are outsourced and

concerns processing and storage of BAM files, VCF files and patient reports. Gross

hourly salaries of the laboratory technician, clinical molecular biologist, and

bioinformatics technician were based on the HMF facility employers' 2018 costs.

Concerning all techniques, costs of acquisition and maintenance of the platforms,

any software acquisition (license), and used consumables exclude Value Added

Taxes (VAT) (Dutch standard rate is 21 %). Utilization percentages are defined

based on 100 % utilization, indicating that the platforms run samples 8 hours a day

and 5 days per week (average working week). All costs are reported in 2018 euros.

1. Base case assumptions for cost calculations of diagnostic

applications based on the standard case perspective.

Base case analysis: Primary outcome

Main cost components and outcomes are displayed in Table 2. A detailed cost

overview including all measured cost items is available and enclosed as

Supplementary Table 2. The total cost per cancer patient per technique varied from €

58 (Sanger, 3 amplicons) to € 4738 (paired tumor-normal WGS). For most

techniques, total per cancer patient costs (including any target gene, hotspot panel or

protein expression subdivisions) were over 90 % attributable to operational costs.

Within this cost category, the most important cost drivers were consumables (for

most > 50 % of operational cost) followed by personnel for sample preparation and

primary data analysis.

Table 2. Process-based cost calculations of diagnostic applications based on

the standard case perspective.

Base case analysis: Secondary outcome

Table 3 depicts a cost overview of most frequently occurring technique

(combinations), including only those techniques used for targeted therapy

stratification based on genomic aberrations, focusing on NSCLC, melanoma, CRC

and GIST. The WGS technique would be a potential future (combinational) indication

of practice use with a year 2018 total cost per cancer patient of € 4738. For WGS no

additional IHC or FISH for detection of fusion genes (e.g. EML4-ALK) is necessary as

is required for NGS gene panels. However, for immunotherapy, sequencing

techniques like NGS and WGS would have to be applied in combination with IHC

protein expression (PD-L1) testing of the tumor, which is not included in Table 3. For

the specific cancer types, the total cost per cancer patient varied between € 58

(Sanger) and € 284 (NGS) for melanoma, € 63 (Sanger) and € 284 (NGS) for CRC, €

69 (Sanger) and € 284 (NGS) for GIST, and technique combinations for NSCLC

15

ranged from € 313 (Sanger and FISH) to € 526 (NGS and FISH).

Table 3. Costs of frequently applied combinations of techniques per cancer

type.□

Sensitivity analysis

The sensitivity analyses demonstrate the impact on the total cost per cancer patient of varying platform utilization (+ / - 15 % standard techniques; + 30 % WGS) and reducing consumable cost by 30 %. In Table 4 the base case total cost, and the range resulting from varying platform utilization and reducing consumable cost, are shown per frequently occurring technique as included in Table 3. In any case, the ranges show overall cost reductions: to illustrate, from \in 284 (average 32 % platform utilization) to \in 250 (17 % platform utilization; - 30 % consumable cost) and \in 216 (47 % platform utilization; - 30 % consumable cost) for NGS gene panels; from \in 204 (average 30 % platform utilization) to \in 166 (15 % platform utilization; - 30 % consumable cost) for IHC (ALK, ROS1); from \in 4738 (average 60 % platform utilization) to \in 3403 (90 % platform utilization; - 30 % consumable cost) for WGS. However, varying platform

platient dimedial, " 35 % containable cooky for 17 35. Flowever, varying platient

utilization has little impact compared to reducing consumable cost, which seems to

have a large impact.

Table 4. Sensitivity analysis.

Discussion

This micro-costing study provides detailed and comparable up to date costs of currently used diagnostic techniques and WGS in the context of predictive analysis for four cancer types. The total cost per cancer patient per technique varied

considerably. For the vast majority of techniques, the operational costs (process of

analysis costs such as consumables and personnel) accounted for over 90 % of the

total per cancer patient technique costs (including any target gene, hotspot panel or

protein expression subdivisions).

Strengths of the study are that the interpretation of each included cost item per cost

category in the measurement plan was aligned extensively for all included techniques

with those parties involved. Furthermore, a consistent and uniform method was used

in performing process-based cost calculations of the application of the different

techniques. Finally, these cost outcomes can be used for (comparative) value

assessments on current and new diagnostic techniques.

In sensitivity analyses, the input parameters were changed (utilization platform

percentage and cost of consumables). A large decrease in costs can be achieved

when costs for consumables might be lower in the future. Even when platform

utilization was reduced, the final total cost was lower for all techniques compared to

the calculated standard case perspective cost. This shows that the cost component

consumables is a more important cost driver than platform utilization.

Comparing our cost outcomes with those initially presented in the literature indicate

that our costs for standard techniques are relatively lower. Roughly estimated, the

extent of reduction was 18 % for single-gene techniques (€ 265 – € 309 (12) versus

on average € 65 – € 405 (Sanger, HRM, IHC, FISH, Biocartis, Cobas, Pyro seg

calculations)) and 58 % for small TGPs of 5 to (~) 50 gene panels (€ 376 – € 968 (12,

15–16) versus on average € 284 (NGS gene panels calculations)). An explanation for

the differences in costs is most probably the different costing methods used and reference year. Our calculated price for WGS (€ 4738) is higher compared to the price by Wetterstrand (\$ 4484 (about € 3870)) (19). Unfortunately, due to a lack of insight in pricing characteristics of previous calculations, we are not able to indicate reasons for this difference. Total cost for all DNA sequencing techniques including WGS is likely to decrease as a result of continuously ongoing innovations and due to market forces, leading to a reduced price of consumables over time, which is the main cost driver (17–18).

It should be stressed that total costs presented per technique are directly related to the test, data analysis and reporting process, so the final cost price indicated in this analysis is not the cost of what a technique costs in its entirety (exclusion of cost obtaining biopsy material, DNA extraction, VAT and overhead). Other excluded costs are, for example, time spend on training, validation, quality assurance and innovation costs (16). Noteworthy, novel genetic biomarkers are continuously emerging. However, these costs of development and implementation of new techniques, or adaptation and validation of existing techniques, are also excluded. Understandably, total cost of techniques is higher when focusing on the entire trajectory. Nonetheless, these outcomes are a snapshot in time, that is, all necessities (platforms, consumables) are strongly in development, especially for DNA sequencing techniques, and are likely to decrease in cost price (17–19). If so, this can easily be changed in our cost tables to calculate new cost prices.

Other factors that should be taken into account when comparing current standard diagnostic techniques and WGS are turnaround time, sensitivity, specificity,

diagnostic yield and quality of the sequencing results. Among other things, the frequency of testing (e.g. number of sequencing runs per week or multiple, sequential, testing), the turnaround time of a sequencing run, time for data analysis and interpretation of results effects the total turnaround time of a sample. The success rate of the sequencing analysis depends on the quantity and quality (biopsy size, tumor volume) of the tumor material, and the amount and quality of DNA extracted (24–25). Subsequently, it determines the number of biopsies to be collected (new material needed when it turns out not to be of sufficient quantity or quality). Rationally, the latter in turn has an impact on waiting time till the start of treatment.

Some limitations of the study need to be addressed. First, this study made an attempt to define realistic assumptions that define the likely cost of application of these techniques in an average lab practice in the Netherlands. Second, for the Dutch labs, the base case assumptions came forth based on a maximum of three labs per included technique, so not all 24 individual labs that helped in defining the most frequently used techniques. As for the HMF facility, the base case assumptions on WGS testing, assuming an average Dutch lab practice, were verified with inhouse experts. Lastly, no data could be obtained for MassArray, which was initially identified as a frequently used technique in treatment of NSCLC and CRC (by one lab), and was therefore not included.

Conclusion

This study provided a detailed overview of all costing aspects and cost prices of current and new diagnostic techniques in treatment of NSCLC, melanoma, CRC and

GIST in the Netherlands. Costs varied between € 58 (Sanger, 3 amplicons) to € 4738 (paired tumor-normal WGS). Costs for commonly used techniques per cancer type varied between € 58 (Sanger) and € 284 (NGS) for melanoma, € 63 (Sanger) and € 284 (NGS) for CRC, € 69 (Sanger) and € 284 (NGS) for GIST, and technique combinations for NSCLC ranged from € 313 (Sanger and FISH) to € 526 (NGS and FISH). The cost of WGS is significantly higher compared to the cost of standard techniques, but it is expected to decrease over time. In terms of value, diagnostic yield is potentially larger with WGS. Though, the study exclusively compared the different techniques based on cost price and not based on their potential value.

Differences in value were not collected in this study, therefore this study can and should be used as starting point in comparing diagnostic modalities. Important to note is that additional factors with regard to value ought to be included to fully assess added benefits (both on monetary as well clinical aspects) of new diagnostic techniques. Future economic evaluations of diagnostic modalities should take into account this difference in value together with the detail costing to give a more comprehensive meaning to the comparison of diagnostic techniques used in cancer treatment. These evaluations support decision-making on implementation of WGS and other diagnostic modalities in routine clinical practice.

Funding sources

This work is part of the research program Personalized Medicine, which is financed by the Netherlands Organisation for Health Research and Development (ZonMw, project numbers 846001001 and 846001002). Other grant providers are the HMF,

the Dutch Cancer Society (KWF Kankerbestrijding) and the Dutch health care insurance company Zilveren Kruis.

Acknowledgements

The authors would like to thank Wim van Harten, Manuela Joore, Martijn Simons, Erik Koffijberg, Maarten IJzerman, Michiel van de Ven and Inge Eekhout from the Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO) consortium, and Astrid Eijkelenboom, Arja ter Elst, Robert van der Geize, Winand Dinjens, Carel van Noesel, Clemens Prinses, Ernst-Jan Speel from the Predictive Analysis for Therapy (PATH) consortium. Furthermore, they would like to express gratitude to the HMF facility and the Dutch pathology laboratories who participated in this study.

References

- Diamandis M, White NM, Yousef GM: Personalized medicine: marking a new epoch in cancer
 patient management. Mol Cancer Res 8(9):1175–87, 2010
- 2. Jackson SE, Chester JD: Personalised cancer medicine. Int J Cancer 137(2):262-6, 2015
- Abdul-Karim RM, Cowey CL: Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Manag Res 9:433–442, 2017
- Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med 373:1627-1639, 2015

- Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373(2):123–135, 2015
- Zorginstituut Nederland: Medicijnkosten.nl, 2/19 update.
 https://www.medicijnkosten.nl/
- 7. Bannon AE, Klug LR, Corless CL, et al: Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn 17(5):445-457, 2017
- 8. Cheng L, Lopez-Beltran A, Massari F, et al: Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 31(1):24-38, 2018
- Kruglyak KM, Lin E, Ong FS: Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Adv Exp Med Biol 890:123-36, 2016
- Sinicrope FA, Okamoto K, Kasi PM, et al: Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol 14(5):651-8, 2016
- Sholl L: Molecular diagnostics of lung cancer in the clinic. Transl Lung Cancer
 Res 6(5):560-569, 2017
- van Amerongen RA, Retèl VP, Coupé VM, et al: Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.
 Ecancermedicalscience 10:684, 2016
- 13. Brittain HK, Scott R, Thomas E: The rise of the genome and personalised medicine. Clin Med (Lond) 17(6):545-551, 2017

- 14. Nakagawa H, Fujita M: Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci 109(3):513-522, 2018
- Sabatini LM, Mathews C, Ptak D, et al: Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn 18(3):319–328, 2016
- Marino P, Touzani R, Perrier L, et al: Cost of cancer diagnosis using nextgeneration sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet 26(3):314-323, 2018
- 17. van Nimwegen KJ, van Soest RA, Veltman JA, et al: Is the \$1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. Clin Chem 62(11):1458–1464, 2016
- Plöthner M, Frank M, Graf von der Schulenburg JM: Cost analysis of whole genome sequencing in German clinical practice. Eur J Health Econ 18(5):623– 633, 2017
- 19. Wetterstrand KA: DNA sequencing costs: Data from the NHGRI genome sequencing program (GSP), 2/19 update. www.genome.gov/sequencingcosts
- 20. Schwarze K, Buchanan J, Fermont JM et al: The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genetics in Medicine 0(0):1–10, 2019
- Lievens Y, Van den bogaert W, Kesteloot K: Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 57(2):522–535, 2003
- 22. U.S. Food and Drug Administration: Drugs, 5/19 update. https://www.fda.gov/drugs

- 23. Casparie M, Tiebosch AT, Burger G, et al: Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19-24, 2007
- 24. Cho M, Ahn S, Hong M, et al: Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget 8(26):42478-42486, 2017
- 25. Morris S, Subramanian J, Gel E, et al: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE 13(4):e0196556, 2018
- 26. Smits AJ, Kummer JA, Hinrichs JW, et al: EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol 35(3):189-196, 2012
- 27. Kerner GS, Schuuring E, Sietsma J, et al: Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One 8(7):e70346, 2013

Table 1. Base case assumptions for cost calculat	ions of diagnosti	c applications ba	sed on the stand	lard case perspec	tive .t														
										Te chniques									
Additional equipment	1	HCE	FIS HE	Pyro seg 🛭	HF	RME		Sai	iger#			NGS II		Cobas		Bioc	artis		WGS#
	Light microscope, Leica	Light microscope, Leica	Hybridizer DAKO, Agilent)								Ion Chef + PCR apparatus	lon Chef + PCR apparatus	PCR a pparatus		ldylla console	ld ylla console	ldy lla console	ldylla console	Biomek 4000
Life cycle additional equipment (years)	10	10	5								5	5	5		10	10	10	10	5
Capacity additional equipment samples per year)!!	7,020	7,020	1,498								666	1,3 3 1	1,331		624	624	624	624	2,496
Pla tform	Ventana. Roche	Ventana. Roche	Fluorescence microscope, Le ice	Pyromark Q 24. Qiagen	LC480, Roche	LC480, Roche	Applied Biosystems, ThemoFisher	Applied Biosystems, ThemoFisher	Applied Biosystems, ThemoFisher	Applied Biosystems, ThemoFisher	I on Torrent PG IV The rmo F is he r	1, lonTorrent PG M ThermoFis her	MiSeq, Illumi na		ldylla, Biocartis	ld ylla, Biocartis		ldylla, Biocartis	No va Seq 6 000, Illumina
Pla tform type	ALK or ROS1	PD-L1	ALK, ROS1 or RET	EGFR+KRAS hots pots 6 amplicons)	EGFR+K RAS+ B RAF hots pots 7-8 amplicons		ABI3 50 0 10 a mp lic ons : EG FR, KRAS, B RAF, ERBB2, MET)	ABI3500 3 amplicons: BRAF, NRAS)	AB I35 00 6 amplicons : KRAS, NRAS, BRAF)	AB 13500 9 amp licons: KIT, PDG FRA, BRAF)	PG M: 316 c hip, cancerhots pot panel v2	PG M: 318 chip, cancerhots pot panel v2	MiSeq: 2 x 150 bp micro v2 kit cancer hotspot panel v2	BRAF	BRAF	EGFR	KRAS	BR AF+ NRAS	
Life cycle platform years)	10	10	10	5	10	10	7	7	7	7	5	5	5	10	5	5	5	5	5
Average coverage (sequencing depth)																			12 0 x
Runs per year!!	260	260	260	2080	780	780	364	364	364	36 4	260	260	260	520	1040	10 40	1040	1040	2 0 8
Samples per run®	90	90	24	4	4	8	96	96	96	96	8	16	16	90	1	1	1	1	24
Capacity, samples per year	23,400	23,400	6,240	8,320	3,120	6,240	34,944	34,944	34,944	34,944	2,080	4,160	4,160	46,800	1,040	1,040	1,040	1,040	4,992
Utilization	30%	30%	24%	8%	56%	28%	54%	54%	54%	54 %	32%	32%	3 2 %	03%	60%	60%	60%	60%	60%
A: tual annual through put	7,020	7,020	1,498	666	1,747	1,747	18,870	18,870	18,870	18,870	666	1,331	1,331	117	624	624	624	624	2 ,9 95
Data processing CPU hours per sample) #											0.1	0.1	0.1						Outsourced
Data storage GB per sample) #											1	1	1						Outsourced
Data storage time years)!!											5	5	5						0.5
Personnel sample preparation and primary data analysis minutes persample)B Personnel data interpretation and report minutes persample)B	15	15	18	108 20	75 16	75 16	233	233	233	23 3 16	345	345	3 4 5	95 16	35 21	35	35	35	120
Softwarell							Seq Patient (JSI)	S eq Pa tie nt JS l)	Seq Pa tient JSI)	Seq Patient (JSI)	Seq Next JSI)	Seq Next (JSI)	Seq Next JSI)						In-house

1 The standard case perspective implies that an average Dutch lab practice was assumed and suppliers' standard list prices were used, in respect of all techniques.

🛮 Additional equipment refers to sample preparation platforms for NGS gene panels and WGS, whereby the unit of sample preparation is sample.

The average coverage (sequencing depth) is based on the standard techniques' specifications of the relevant suppliers. The 120x coverage for WGS corresponds to 2 samples (also 1 cancer patient) and consists of 90x tumor coverage (3 times for heterogeneity) and 30x blood coverage (1 time as a reference genome).

12 The unit of 1 flow cell is 30x coverage. In 1 run 2 flow cells of each 30x coverage fit. So, in 2 runs 4 flow cells fit, which corresponds to the 120x coverage for WGS.

Data processing and data storage are outsourced for WGS.

2 Data storage time concerns 6 months of hot storage of a BAM file, VCF file and patient report for WGS.

The sample preparation and primary data analysis is done by a laboratory and bioinformatics technician for the standard techniques, and by a laboratory technician only for WGS. Sample and report administration is incorporated for all techniques.

🛚 The data interpretation and report is done by a clinical molecular geneticist and pathologist for the standard techniques, and by a clinical molecular geneticist and a bioinformatics technician for WGS.

🛮 In-house refers to in-house pipeline experience, for example, Burrows-Wheeler Aligner (BWA), Genome Analysis Toolkit (GATK), Strelka, BLCtoFASTQ, sebamba, PURPLE for WGS.

Including immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), pyrosequencing (Pyro seq), High Resolution Melting (HRM), Sanger sequencing (Sanger), next generation sequencing (NGS) and whole genome sequencing (WGS).

Table 2. Process-based cost calculations of diagnostic	1																		
							1			Tech niques									-
		HCIII	FIS HI	Pyro seq∄	Н	RM⊞		Sa	nger 🛚			NGS⊞		Cobas		Biod	artis		WGS⊞
Ad ditional equipment	Light microscope, Leica	Light microscope, Leica	Hybridizer DAKO, Agilent)								lon Chef + PCR apparatus	lon Chef + PCR apparatus	PCR apparatus		Idylla console	Idylla console	ld ylla console	ld ylla console	Biome k 4000
Pla tfor m	Venta na , Roche	Ventana, Roche	Fluores cence micros cope, Leica	Pyromark Q24, Qiagen	LC 480, Roc he	LC480, Roche	Applied Bios ys tems, Themo Fis her	Applied Bios ys tems, Themo Fis her	Applied Biosystems, The moFisher	Applied Biosystems, ThemoFisher	lonTorrent PGM, ThermoFisher	lonTorrent PGM, ThermoFisher	MiSeq, Illumina	Cobas, Roche	ldylla, Biocartis	ldylla, Biocartis	ld ylla, Biocartis	ld yl la, Biocartis	NovaSeq 6000 Illumina
Platform type	ALK or ROS1	PD-L1	ALK, ROS1 or RET	EGFR+KRAS hots pots 6 amplicons)	EGFR+KRAS+B RAF hots pots 8 amplicons)	BRAF+NRAS 3 a mplicons)	ABI3 500 10 amplicons : EG FR, K RAS, BRAF, ERBB2, MET)	ABI3500 3 amplicons: BRAF, NRAS)	ABI35 00 6 amplicons: KRAS, NRAS, BRAF)	ABI3500 9 amplicons: KIT, PDGFRA BRAF)	PG M: 3 16 chip, cancer hots pot panel v2	PG M: 3 18 chip, cancerhots pot panel v2	MiSeq: 2x150 bp micro v2 kit, cancer hots pot panel v2	BRAF	BRAF	EGFR	K RAS	BRAF+N RAS	
Utilization	3 0%	3 0%	24%	8%	5 6%	2.8%	54%	54%	54%	54%	32 %	32%	32%	03%	60%	60%	60%	60%	60%
Actual annual throughput	7,020	7,020	1,498	666	1.747	1,747	18,870	18,870	18,870	18,870	666	1,331	1,331	117	624	624	624	62 4	2,995
Capital costs	,,		1-1			1 1 1 1							1=1===	1==:		1	1		12,222
Additional equipment initial costs	€ 5 0.000 00	€ 50.000.00	€ 6.679.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€0.00	€ 0.00	€ 9.000.00	€ 9 000 00	€ 9.000.00	€ 0.00	€ 5 000.00	€ 5.000,00	€ 5.000,00	€ 5.000.00	€ 80.000.00
Platform initial costs #	€ 15,000,00	€ 15.000.00	€ 70.000,00	€ 70.944.00	€ 65.000.00	€ 65.000.00	€ 13 6.5 00.00	€ 136.500.00	€ 136.500.00	€ 13 6.5 00.00	€ 61.897.00	€ 61.897.00	€ 95.811.00	€ 64.060.37	€ 45.000.00	€ 45.000.00	€ 45.000.00	€ 45.000.00	€ 761.000.00
Annual capital costs additional equipments	€ 6,318.94	€ 6.318.94	€ 1,521.42	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€0.00	€ 0.00	€ 2,050.12	€ 2,050.12	€ 2,050.12	€ 0.00	€ 631.89	€ 631.89	€ 63 1.89	€ 63 1.89	€ 17,970.17
Annual capital costs platform	€ 1,895.68	€ 1,895.68	€ 8,846.52	€ 16,160.45	€ 8.214.62	€ 8,214.62	€ 23,164.25	€ 23,164.25	€ 23,164.25	€ 23,164.25	€ 14,099.62	€ 14,099.62	€ 2 1,82 4.9 4	€ 8,095.87	€ 10,250.62	€ 10,250.62	€ 10,250.62	€ 10,250.62	€ 170,941.23
	€ 1.17	€ 1,895.08	€ 6,846.32	€ 24.28	€ 4.70	€ 4.70	€ 23,164.23	€ 1.23	€ 123	€ 23,164.23	€ 24.26	€ 14,099.62	€ 17.93	€ 29.66	€ 17.44	€ 17.44	€ 17.44	€ 10,250.62	
Capital costs per sample or per tumor norma 🕅	€ 1.1/	€ 1.1/	€ 6.92	E 24.20	€ 4.70	€ 4.70	€ 1.23	€ 1.23	E 123	€ 1.23	€ 24.26	€ 12.13	€ 17.95	€ 29.00	€ 17.44	€ 17.44	E 17 #4	€ 17.44	€ 242.69
Maintenance costs Annual maintenance costs additional equipment other years) ■	€ 5,000.00	€ 5,000.00	€ 200.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0 0 0	€ 0.00	€ 9 00.00	€ 900.00	€ 9 00 00	€ 0.00	€ 500.00	€ 5 00 .00	€ 500.00	€ 500.00	€ 3,000.00
Annual maintenance costs platform other years)	€ 5 00 .00	€ 500.00	€ 1,000.00	€ 6,500.00	€ 3,148.00	€ 3,148.00	€ 3,655.00	€ 3,655.00	€ 3,655.00	€ 3,655.00	€ 6,100 00	€ 6,100 Д0	€ 11,867.00	€5,200.00	€ 4,000.00	€ 4,000.00	€ 4,000.00	€ 4,000 00	€ 64,000.00
An nual maintenance costs	€ 4,950.00	€ 4,950.00	€ 1,060.00	€ 5,200.00	€ 2,833.20	€ 2,833.20	€ 3,132.86	€ 3,132.86	€ 3,132.86	€ 3,132.86	€ 5,600.00	€ 5,600 00	€ 10,213.60	€ 4,680.00	€ 3,650.00	€ 3,650.00	€ 3,650.00	€ 3,650.00	€ 53,600.00
Maintenance costs per sample or per tumor norma 🛭	€0.71	€ 0.71	€ 0.71	€ 7.81	€ 1.62	€ 1.62	€ 0.17	€ 0.17	€ 0.17	€ 0.17	€841	€ 4.21	€ 7.67	€ 17.14	€ 5.85	€ 5.85	€ 5.85	€ 5.85	€ 87.87
Software costs																			
Ageuisition software costs II							€ 2,000.00	€ 2,000.00	€ 2,000.00	€ 2,000.00	€ 20,000.00	€ 20,000.00	€ 20,000.00						
Annual software management / maintenance costs:																			€ 400.00
Annual software costs							€ 2,000.00	€ 2,000.00	€ 2,000.00	€ 2,000.00	€ 3,500.00	€ 3,500 00	€ 3,500.00						€ 400.00
Software costs per sample or per tumor normalill	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.11	€ 0.11	€0.11	€ 0.11	€526	€ 2.63	€ 2.63	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.16
Operational costs																			
Sample preparation and quality control consumables per sample⊠	€ 69.10	€ 60.96	€ 79.60	€ 319.05	€ 46.13	€ 23 D7	€ 19.30	€ 5.79	€ 11.58	€ 17.37	€ 106.48	€ 106.48	€ 14057	€ 251.74	€ 140.00	€ 250.00	€ 190.00	€ 250.00	€ 100.00
Consumables persample#					€ 3.57	€ 3.57					€ 120.29	€ 81.19	€ 33.75	€ 7.78					€ 4,000.00
Data processing per CPU hour / IT infra per tumor normal)	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€0.01	€ 0.01	€0.01	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 0.10	€ 200.00
Data storage per GBs torage per year) 🗵	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€0.01	€ 0.01	€0.05	€ 0.05	€0.05	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.01	€ 24.00
Personnel sample preparation and primary data analysis per sample⊞	€ 20.59	€ 20.59	€ 32.71	€ 37.14	€ 2858	€ 2858	€ 37.38	€37.38	€ 37.38	€ 37.38	€ 50.82	€ 42 .08	€ 42.08	€ 33.02	€ 28.05	€ 28.05	€ 28.05	€ 28.05	€ 50.00
Personnel data interpretation and report per sample⊞	€ 10.21	€ 1021	€ 14.43	€ 16.98	€ 1290	€ 1290	€ 12.90	€ 12.90	€ 12.90	€ 12.90	€ 14.26	€ 14.26	€ 14.26	€ 12.90	€ 16.29	€ 16.29	€ 1629	€ 16.29	€ 33.33
Operational costs per sample or per tumor norma 🛭	€ 100.01	€91.87	€ 126.85	€ 373.28	€9129	€ 68.23	€ 69.69	€ 56.18	€ 61.97	€ 67.76	€291.91	€ 244.07	€230.72	€ 3 05 .54	€ 184.45	€ 294.45	€ 234.45	€ 294.45	€ 4,407.33
Total costs per cancer patient®	€ 101.88	€ 93.74	€ 134.48	€ 405.37	€ 97.62	€ 74.56	€ 71.19	€ 57.68	€ 63.47	€ 69.26	€ 329.85	€ 263.04	€ 258.96	€ 352.34	€ 207.74	€ 317.74	€ 257.74	€ 317.74	€ 4.738.05

The standard case perspective implies that an average Dutch lab practice was assumed and suppliers' standard list prices were used, in respect of all techniques.

The cost of the platforms, software and consumables all exclude Value Added Taxes (VAT).

☐ For the standard diagnostic techniques, life cycles varying between 5 to 10 years, annuity factors ranging between 4.39 to 7.91, and an interest rate of 4.5 % are maintained for both types of equipment (if applicable). The annual capital costs of the additional equipment (sample preparation platform) and the sequencing platform for WGS are calculated by taking into account a life cycle of 5 years, an annuity factor of 4.45 and an interest rate of 4 %.

The capital, maintenance and operational costs per sample calculations are based on 2 times sample preparation and 4 times genome sequencing (90x coverage tumor and 30x coverage blood) for WGS. For WGS application, two samples are needed (tumor biopsy and blood) to do the analysis whereas for the standard used techniques 1 sample (tumor) suffices.

2 During the first year no maintenance costs occur as the platforms have a warranty for the first year.

■ Software management / maintenance incorporates daily supervision and maintenance of the pipeline for WGS. It takes up 0.2 FTE (of a 40-hour working week) for a bioinformatics technician with a gross hourly salary of € 50.

- ☐ Data processing and data storage are outsourced for WGS. The cost of data processing covers the complete analysis of raw data to BAM file, VCF file and patient report. The cost of data storage is estimated based on hot storage of the BAM file, VCF file and patient report for 6 months (€ 4 per month per 200 GB).
- ☑ The sample preparation and primary data analysis is done by a laboratory technician (gross hourly salary of € 22) and bioinformatics technician (gross hourly salary of € 29) for the standard techniques. For WGS this is performed by a laboratory technician (gross hourly salary of €25). Sample and report administration is incorporated for all techniques.
- ☑ The data interpretation and report per sample is done by a clinical molecular biologist (gross hourly salary of € 41) and pathologist (gross hourly salary of € 61) for the standard techniques. For WGS this is performed by a clinical molecular biologist and a bioinformatics technician, both with a gross hourly salary of €50.
- The total cost per cancer patient represents a total cost per target gene separately for IHC (ALK or ROS1) and FISH (ALK, ROS1 or RET). A combined total cost per cancer patient of the specified target genes per technique is given for Pyro seq, HRM (EGFR + KRAS + BRAF; BRAF + NRAS) and Biocartis (BRAF + NRAS), and for Sanger (10, 3, 6, 9 amplicons) and NGS hotspot panels.
- 🗵 Including immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), pyrosequencing (Pyro seq), High Resolution Melting (HRM), Sanger sequencing (Sanger), next generation sequencing (NGS) and whole genome sequencing (WGS).

				Techniques			
	NGS	Sanger	HRM	IHC	FISH	WGS	Total cost per cancer patient
	PGM 316, 318 chip; MiSeq	ABI3500 (10/3/6/9 amplicons)2	BRAF+NRAS	ALK+ROS1	ALK+ROS1+ RET		
NSCLC222							
Test 1	€ 283.95			€ 203.77			€ 487.72
Test 2🛚	€ 283.95				€ 242.07		€ 526.01
Test 3🛭		€ 71.19			€ 242.07		€ 313.26
Melanoma2							
Test 1	€ 283.95						€ 283.95
Test 2			€ 74.56				€ 74.56
Test 3		€ 57.68					€ 57.68
CRC2 2							
Test 1	€ 283.95						€ 283.95
Test 2		€ 63.47					€ 63.47
GIST2 2							
Test 1	€ 283.95						€ 283.95
Test 2		€ 69.26					€ 69.26
All							
						€ 4,738.05	€ 4,738.05

☑ Overall, included standard techniques were performed in ≥ 2 labs (inventory labs) and included ≥ 5 % of the analyses in total for the respective cancer types (PALGA data) (Supplementary Table 1). These techniques covered at least 80 % of the performed analyses per cancer type (PALGA data). WGS usage is a potential future practice expectation for all cancer types. The total cost per technique represents a combined total cost, which is calculated based on their analysis of target genes (IHC, FISH, HRM) or hotspot panels (Sanger, NGS). For NGS, an average of the total cost of the three different platforms was used for the calculations.

Test 1, 2 (and 3) show the descending order of frequency usage of technique (combinations).

Programme For NSCLC, the techniques included in test 1 are concomitantly applied (100 %) and those incorporated in test algorithm 2 and 3 are sequential applied (< 100 %), only when the prior test is negative.

[🛮] The total cost for FISH is based on 60 % frequency usage of ALK, ROS1 and RET (sequential testing: in 40 % of cases a mutation in EGFR or KRAS is observed, and consequently FISH is not performed) (26-27).

The genes tested with Sanger are EGFR, KRAS, BRAF, ERBB2 and MET (10 amplicons) for NSCLC; BRAF and NRAS (3 amplicons) for melanoma; KRAS, NRAS and BRAF (6 amplicons) for CRC; KIT, PDGFRA and BRAF (9 amplicons) for GIST.

² Including non-small cell lung carcinoma (NSCLC), colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST).

🗵 Including next generation sequencing (NGS), Sanger sequencing (Sanger), High Resolution Melting (HRM), immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH) and whole genome sequencing (WGS).

Table 4. Sensitivity analysis.																
		Techniques 2 2														
	NGSಔ		Sar	nger		HRM	IHC	FISH	WGS							
	1	,	,	,	ABI3500 (9 amplicons)	BRAF+NRAS	ALK+ROS1	ALK+ROS1+RET								
Standard case perspective	€ 283.95	€ 71.19	€ 57.68	€ 63.47	€ 69.26	€ 74.56	€ 203.77	€ 403.45	€ 4,738.05							
Range of practice2	€ 250.11 - 216.01	€ 65.98 - 65.07	€ 56.52 - 55.62	€ 60.57 - 59.67	€ 64.63 - 63.72	€ 73.86 - 64.36	€ 166.06 - 161.06	€ 369.96 - 323.00	€ 3,403.47							

[☑] Currently most frequently used techniques in cancer types of focus.

[🛮] The average total cost of the cost calculation outcomes for the NGS platforms and different hotspot panels is used.

[☐] The utilization of the platforms varied from 17 to 47 % for NGS (average 32 %), 39 to 69 % for Sanger (average 54 %), 13 to 43 % for HRM (average 28 %), 15 to 45 % for IHC (average 30 %), 9 to 39 % for FISH (average 24 %) and 60 % to 90 % for WGS. The cost of consumables were reduced by 30 % for all the techniques.

Including next generation sequencing (NGS), Sanger sequencing (Sanger), High Resolution Melting (HRM), immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH) and whole genome sequencing (WGS).

Supplementary tables

Table S1. Per	centage frec	uency usage	techniques p	er cancer t	ype (PALGA,	2018).🛚										
		Techniques 🛭														
		NGS + other														
	NGS	technique	MassArray	HRM	Sanger	Pyro seq	Biocartis	Cobas	Other	Unknown						
NSCLC᠌	78	5	3	4	5	3	1	0	0	0						
Mel a noma	57	8	15	6	5	1	4	1	1	0						
CRC	80	2	2	4	7	2	3	0	0	0						
GIST᠌	78	16	0	0	6	0	0	0	0	0						

Online only.

[🛮] Including non-small cell lung carcinoma (NSCLC), colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST).

[🛮] Including next generation sequencing (NGS), High Resolution Melting (HRM), Sanger sequencing (Sanger) and pyrosequencing (Pyro seq)

Table S2. Process-based cost calculations of diagnostic	applications based	on the standard ca	se perspective.III																
•				1						e chniques					1				
		ICH	FISHE	Pyro seq#	HF	RME	***************************************	Sa	ngerä			NGSE		Cobas			cartis	Tv	WGS
Ad ditional equipment	Light mic rosc ope, Leica	Light microscope, Leica	Hybridizer DAKO, Agilent)								lon Chef + PCR apparatus	lon Chef + PCR apparatus	PCR apparatus		ldylla console	ldylla console	ldy I la console	l dy lla c onso le	Biomek 4 000
Life cycle additional equipment (years)	10	10	5								5	5	5		10	10	10	10	5
Capacity additional equipment per year	7,020	7,020	1,498								666	1,331	1,331		624	6 24	624	6 2 4	2,496
Platform	Ventana, Roche	Ventana, Roche	Fluorescence microscope, Leica	Pyromark Q24, Qiagen	LC480, Roche	LC 48 0, Roche	Applied Biosystems, The moFisher	Applied Biosystems, The moFisher	Applied Biosystems, The moFisher	Applied Biosystems, The moFisher	lonTorrent PG M, ThermoFisher	lonTorrent PGM, Thermo Fisher	MiSeq, Illumina	Cobas, Roche	ldylla. Biocartis	ldylla, Biocartis	ldylla, Biocartis	ldylla, Biocartis	NovaSeq 6000 Illumina
Pla tform type	ALK or ROS1	PD-L1	ALK, ROS1 or RET	EGFR+KRAS hots pots 6 amplicons)	EG FR+K RAS+B RAF hots pots 7-8 amplicons	BRAF+NRAS 3 amplicons	ABI3500 10 amplicons: EGFR, KRAS, BRAF, ERBB2, MET)	ABI3500 3 amplicons: BRAF, NRAS)	ABI3500 6 a mplico ns: KRAS, NRAS, BRAF)	ABI3500 9 amplicons: KIT, PDG FRA BRAF)	PG M: 316 c hip, cancer hots pot panel v2	PGM: 318 chip, cancerhots pot panel v2	MiSeq: 2x 150 bp micro v2 kit, cancer hots pot panel v2	BRAF	BRAF	EGFR	KRAS	BRAF+ NRAS	
Life cycle platform (years)	10	10	10	5	10	10	7	7	7	7	5	5	5	10	5	5	5	5	5
Utilization	30%	30%	2 4 %	8 %	56%	28%	54%	54%	54%	54%	32%	32%	32%	0 .3%	60%	6 0%	60%	60%	6 0%
A: tual annual throughput	7,020	7,020	1,498	666	1,747	1,747	18,870	18,870	18,870	18,870	666	1,3 3 1	1,331	117	624	6 24	624	624	2,995
Capital costs																			_
Additional equipment initial costs #	€ 50,000.00	€50,000.00	€6,679.00	€0.00	€ 0.00	€000	000€	€0.00	€ 0.00	€ 0.00	€ 9,000.00	€9,000.00	€ 9,000.00	0.00	€ 5,000 00	€ 5,000.00	€5,000.00	€ 5,000.00	00.000,08€
Life cycle additional equipment (years)	10	10	5	1	1	1	1	1	1	1	5	5	5	1	10	10	10	10	5
Pla tform initial costs#	€ 15,000.00	€ 15,000.00	€70,00000	€ 70,944.00	€ 65,000 00	€ 65,000.00	€ 136,500.00	€ 136,500.00	€ 136,500.00	€ 136,500.00	€ 61,897.00	€ 61,897.00	€ 95,811.00	€ 64,06037	€45,000.00	€ 45,000.00	€45,000.00	€ 45,000.00	€ 76 1,000 00
Life cycle platform years)	10	10	10	5	10	10	7	7	7	7	5	5	5	10	5	5	5	5	5
Interest rate 0-1)	0.05 7.91	0.05	0.05 4.39	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05 4.39	0.05	0.05	0 .05	0.05	0.05 7.91	0.05 7.91	0.05	0.04 4.45
An nuity factor additional equipment An nuity factor platform	7.91 7.91	791 791	7.9.1	4.39	7.91	7.91	5.89	5.89	5.89	5.89	4.39	4.39	4.39	7.91	7.91 4.39	4.39	7.91 4.39	7.91 4.39	4.45
Annuity factor platform Annual capital costs additional equipments	791 €6,31894	791 €6,318.94	€ 1,52 1.42	€0.00	€ 0.00	7.91 €000	€0.00	€0.00	€ 0.00	€ 0.00	€ 2,050.12	€ 2,050.12	€ 2,050.12	7.91 € 0.00	439 €63189	€ 631.89	€631.89	4.39 €631.89	€ 17,970.17
Annual capital costs platformil	€ 1.895.68	€ 1,895.68	€ 8,84652	€ 16.160.45		€ 8.2 14.62	€ 23,164.25	€ 23, 164.25	€ 23.164.25	€ 23,164.25	€ 14.099.62	€ 14.099.62	€ 21.824.94	€ 8.095.87	€ 10.250.62	€ 10.250.62	€ 10.250.62	€ 10.250.62	€ 17.570.17
Annual capital costs additional equipment sample	€ 1,093.00	€ 1,035.00	€ 0,04032	€ 10,100.45	€ 0,214.02	€ 0,2 14.02	€23,164.23	€ 23, 104.23	€ 23, 164.23	£ 23, 16 4 25	€ 14,099.62	€ 14,099.62	£ 21,824.94	E 0,09567	£ 10,250 B 2	€ 10,250 82	€ 10,230.62	€ 10,250.62	€ 1/0,94123
preparation platform) Annual capital costs sequencing per 30 x cov										1									€ 57 .07
Capital costs per sample or per tumor normal?	€ 1.17	€ 1.17	€ 6.92	€ 24.28	€ 4.70	€ 4.70	€ 1.23	€ 1.23	€ 1.23	€ 1.23	€ 24.26	€ 12.13	€ 17.93	€ 29.66	€ 17.44	€ 17.44	€ 17.44	€ 17.44	€ 242.69
Maintenance costs																			
Annual maintenance costs additional equipment first year)	€ 0.00	€000	€0.00	€0.00	€ 0.00	€000	€000	0.00	€ 0.00	€ 0.00	€ 0.00	€0.00	000€	€ 0.00	000€	€ 0.00	0.00	000€	€ 0.00
An nual maintenance costs additional equipment other years)	€ 5,000 £0.00	€ 5 ,0 00 .00 € 0 .0 0	€ 2 00 .00	€0.00	€ 0.00	€000	€0.00	€0.00	€ 0.00	€ 0.00	00.00€ €	€90000	€ 900.00	€ 0.00	€500£0 €0£0	€ 500.00	€500.00	€ 500.00	€ 3,000.00
Annual maintenance costs platform first year) Annual maintenance costs platform other years)	€ 500.00	€50000	€ 1,000,00	€6,500.00	€ 3,148,00	€ 3,148.00	€3,655.00	€3,655.00	€ 3,655.00	€ 3,655.00	€ 6,100.00	€ 6,100 00	€ 11,867.00	€ 5,200,00	€ 4,000 ДО	€ 4,000.00	€4,000.00	€ 4,000,00	€ 64,000.00
Annual maintenance costs	€ 4,950.00	€ 4,950.00	€ 1,060.00	€5,200.00	€ 2,833 20	€ 2,833.20	€3,132.86	€3,132.86	€ 3,132.86	€ 3,132.86	€ 5,600.00	€5,600.00	€ 10,213.60	€4,680,00	€ 3,650 00	€ 3,650.00	€3,650.00	€ 3,650.00	€ 53,600.00
An nual maintenance costs additional equipment																			€ 1.20 € 21.37
An nual maintenance costs sequencing per 30 xcov Maintenance costs per sample or per tumor norma 🖪	6071	€0.71	€0.71	€7.81	€ 1.62	€ 162	€0.17	€0.17	€ 0.17	€ 0.17	€8.41	€4.21	€767	€ 17.14	€ 5.85	€ 5.85	€5.85	€ 5.85	€ 87.87
Software costs			100.2	C7.02	. 1.02	10.202	10.27	100.27	100.27	10.27	10.0.42	107.2.2	10727	. 17.114		C 3.03	103.03		C 07 27
Against ition software costs#							€2,000.00	€2,000.00	€ 2,000.00	€ 2,000.00	€ 20,000 00	€20,000.00	€ 20,000.00						
Life cyc les oftware years)							1	1	1	1	10	10	10						
An nual software management / maintenance costs#																			€40000
Annual software costs	€0.00	€0.00	0.00 €	€0.00	€ 0.00	€ 0.00	€2,000.00	€2,000.00	€ 2,000.00	€ 2,000.00	€ 3,500.00	€3,500.00	€ 3,500.00	0.00	0.00	€ 0.00	0.00	0.00	€40000
Software costs per sample or per tumor normaনিটা	€ 0.00	€0.00	0 0 0 €	€0.00	€ 0.00	000	€0.11	€0.11	€ 0.11	€ 0.11	€5.26	€ 2.63	€263	€ 0.00	€0.00	€ 0.00	0.00	000€	€ 0.16
Operational costs Sample preparation and quality control																			€ 50 00
consumables per 30 x cov# Sample preparation and quality control consumables per sample#	€ 69.10	€60.96	€79.60	€31905	€ 46.13	€ 23.07	€ 19.30	€5.79	€ 11.58	€ 17.37	€ 106.48	€ 10648	€ 140.57	€ 25 1.74	€ 14000	€ 250 ДО	€ 190.00	€ 250.00	€ 10000
Sequencing consumables per 30x cov®																			€ 1,000.00
Consumables per sample!!					€ 3.57	€357					€ 120.29	€81.19	€ 33.75	€7.78					€ 4,000.00
Data processing per CPU hour / IT infra per tumor	€ 0.10	€0.10	€ 0.10	€0.10	€ 0.10	€ 0.10	€0.10	€0.10	€ 0.10	€ 0.10	€ 0.01	€0.01	€001	€ 0.10	€ 0.10	€ 0.10	€0.10	€ 0.10	€ 20000
normal)II	€ 0.01	£0.01	£ 0.01	€ 0.0.1		€0.01	£ 0 .0 1	€0.01	€ 0.01	£ 0.01	£ 0.05	€0.05	£ 0.05	€ 0.01	€ 0.01	€ 0.01	€0.01	€ 0.01	£ 24.00
Datastorage per GB storage per year)!! Personnel sample preparation and primary data	€ 0.01 € 20.59	€0.01	€ 0.01	€ 0.01	€ 0.01 € 28.58	€ 0.01	€0.01	€ 0.01	€ 0.01	€ 0.01	€ 0.05	€ 42.08	€ 0.05	€ 0.01	€0.01 €28.05	€ 28.05	€0.01	€0.01 €28.05	€ 24 00
analysis persample!! Personnel data interpretation and report per	€ 10 2 1	€ 10.21	€ 14.43	€ 16.98	€ 12.90	€ 12.90	€ 12.90	€ 12.90	€ 12.90	€ 12.90	€ 14.26	€ 14.26	€ 42.08	€ 12.90	€ 1629	€ 16.29	€ 16.29	€ 16 29	€ 33.33
sample!! Operational costs per sample or per tumor normal!!	€ 100.01	€91.87	€ 126.85	€37328	€ 91.29	€ 68.23	€69.69	€56.18	€ 61.97	€ 67.76	€ 291.91	€24407	€ 230.72	€ 305.54	€ 184.45	€ 294 45	€ 234.45	€ 294.45	€ 4,407.33
	€ 101.88	€93.74	€ 134.48	€ 405.37	€ 97.62	€ 74.56	€71.19	€57.68	€ 63.47	€ 69.26	€ 329.85	€263.04	€ 258.96	€ 352.34	€ 207.74	€ 317.74	€ 257.74	€ 3 17.74	€ 4,738.05

- 2 Online only.
- 12 The standard case perspective implies that an average Dutch lab practice was assumed and suppliers' standard list prices were used, in respect of all techniques.
- 2 The cost of the platforms, software and consumables all exclude Value Added Taxes (VAT).
- ☐ For the standard diagnostic techniques, life cycles varying between 5 to 10 years, annuity factors ranging between 4.39 to 7.91, and an interest rate of 4.5 % are maintained for both types of equipment (if applicable). The annual capital costs of the additional equipment (sample preparation platform) and the sequencing platform for WGS are calculated by taking into account a life cycle of 5 years, an annuity factor of 4.45 and an interest rate of 4 %.
- The capital, maintenance and operational costs per sample calculations are based on 2 times sample preparation and 4 times genome sequencing (90x coverage tumor and 30x coverage blood) for WGS. For WGS application, two samples are needed (tumor biopsy and blood) to do the analysis whereas for the standard used techniques 1 sample (tumor) suffices.
- 2 During the first year no maintenance costs occur as the platforms have a warranty for the first year.
- ② Software management / maintenance incorporates daily supervision and maintenance of the pipeline for WGS. It takes up 0.2 FTE (of a 40-hour working week) for a bioinformatics technician with a gross hourly salary of € 50.
- ☐ Data processing and data storage are outsourced for WGS. The cost of data processing covers the complete analysis of raw data to BAM file, VCF file and patient report. The cost of data storage is estimated based on hot storage of the BAM file, VCF file and patient report for 6 months (€ 4 per month per 200 GB).
- ☑ The sample preparation and primary data analysis is done by a laboratory technician (gross hourly salary of € 22) and bioinformatics technician (gross hourly salary of € 29) for the standard techniques. For WGS this is performed by a laboratory technician (gross hourly salary of €25). Sample and report administration is incorporated for all techniques.
- ☑ The data interpretation and report per sample is done by a clinical molecular biologist (gross hourly salary of € 41) and pathologist (gross hourly salary of € 61) for the standard techniques. For WGS this is performed by a clinical molecular biologist and a bioinformatics technician, both with a gross hourly salary of €50.
- The total cost per cancer patient represents a total cost per target gene separately for IHC (ALK or ROS1) and FISH (ALK, ROS1 or RET). A combined total cost per cancer patient of the specified target genes per technique is given for Pyro seq, HRM (EGFR + KRAS + BRAF; BRAF + NRAS) and Biocartis (BRAF + NRAS), and for Sanger (10, 3, 6, 9 amplicons) and NGS hotspot panels.
- Including immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), pyrosequencing (Pyro seq), High Resolution Melting (HRM), Sanger sequencing (Sanger), next generation sequencing (NGS) and whole genome sequencing (WGS).